The Science Behind the DEA's Long War on Marijuana
Scientific American
Sen. Merkley and Rep. Blumenauer join Tyson Haworth, owner of Oregon's Finest & sofresh farms, to discuss the banking and tax challenges that legal cannabis companies are facing under current federal law.
“You want to know what this was really all about?” asked Watergate conspirator Ehrlichman. “The Nixon campaign in 1968, and the Nixon White House after that, had two enemies: the antiwar left and black people. We knew we couldn’t make it illegal to be either against the war or black, but by getting the public to associate the hippies with marijuana and blacks with heroin, and then criminalizing both heavily, we could disrupt those communities.”
TPP's fate in congress is uncertain at best; Long-awaited text reveals gaps between administration claims and actual TPP terms on key congressional, public concerns. Many in Congress said they would support the TPP only if, at a minimum, it included past reforms made to trade pact intellectual property rules affecting access to affordable medicines. But the TPP rolls back that past progress and provides pharmaceutical firms with new monopoly rights for biotech drugs.
Pharmaceutical companies spend billions of dollars marketing drugs to doctors. We have a few issues with that.
As long as this commerce is illegal, it is totally unregulated. Since we know that addicts will continue to buy drugs on the street, we also know that some will die from drugs that are either too potent or adulterated with other substances that could make them lethal. Is this really the intent of our drug policy? To invite users to kill themselves?
Spread the word